CY1113409T1 - Αναστολεις ακτ και ρ70 s6 κινασης - Google Patents

Αναστολεις ακτ και ρ70 s6 κινασης

Info

Publication number
CY1113409T1
CY1113409T1 CY20121100928T CY121100928T CY1113409T1 CY 1113409 T1 CY1113409 T1 CY 1113409T1 CY 20121100928 T CY20121100928 T CY 20121100928T CY 121100928 T CY121100928 T CY 121100928T CY 1113409 T1 CY1113409 T1 CY 1113409T1
Authority
CY
Cyprus
Prior art keywords
acth
formula
suspension suspensions
compounds
present
Prior art date
Application number
CY20121100928T
Other languages
Greek (el)
English (en)
Inventor
Robert Dean Dally
Sajan Joseph
Timothy Alan Shepherd
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1113409T1 publication Critical patent/CY1113409T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CY20121100928T 2008-11-11 2012-10-05 Αναστολεις ακτ και ρ70 s6 κινασης CY1113409T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11327308P 2008-11-11 2008-11-11
EP09744896A EP2358710B1 (en) 2008-11-11 2009-11-03 Akt and p70 s6 kinase inhibitors

Publications (1)

Publication Number Publication Date
CY1113409T1 true CY1113409T1 (el) 2016-06-22

Family

ID=41402451

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100928T CY1113409T1 (el) 2008-11-11 2012-10-05 Αναστολεις ακτ και ρ70 s6 κινασης

Country Status (36)

Country Link
US (1) US8148387B2 (cg-RX-API-DMAC7.html)
EP (1) EP2358710B1 (cg-RX-API-DMAC7.html)
JP (1) JP5432275B2 (cg-RX-API-DMAC7.html)
KR (1) KR101334460B1 (cg-RX-API-DMAC7.html)
CN (1) CN102216302B (cg-RX-API-DMAC7.html)
AR (1) AR074072A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009314324B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0921916A2 (cg-RX-API-DMAC7.html)
CA (1) CA2743019C (cg-RX-API-DMAC7.html)
CO (1) CO6382114A2 (cg-RX-API-DMAC7.html)
CR (1) CR20110240A (cg-RX-API-DMAC7.html)
CY (1) CY1113409T1 (cg-RX-API-DMAC7.html)
DK (1) DK2358710T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2011000129A (cg-RX-API-DMAC7.html)
EA (1) EA018947B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP11011048A (cg-RX-API-DMAC7.html)
ES (1) ES2391704T3 (cg-RX-API-DMAC7.html)
HN (1) HN2011001247A (cg-RX-API-DMAC7.html)
HR (1) HRP20120738T1 (cg-RX-API-DMAC7.html)
IL (1) IL211940A (cg-RX-API-DMAC7.html)
JO (1) JO2822B1 (cg-RX-API-DMAC7.html)
MA (1) MA32776B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011005000A (cg-RX-API-DMAC7.html)
MY (1) MY161461A (cg-RX-API-DMAC7.html)
NZ (1) NZ592062A (cg-RX-API-DMAC7.html)
PA (1) PA8846901A1 (cg-RX-API-DMAC7.html)
PE (1) PE20110807A1 (cg-RX-API-DMAC7.html)
PL (1) PL2358710T3 (cg-RX-API-DMAC7.html)
PT (1) PT2358710E (cg-RX-API-DMAC7.html)
RS (1) RS52520B (cg-RX-API-DMAC7.html)
SI (1) SI2358710T1 (cg-RX-API-DMAC7.html)
TN (1) TN2011000207A1 (cg-RX-API-DMAC7.html)
TW (1) TWI422587B (cg-RX-API-DMAC7.html)
UA (1) UA100190C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010056563A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201102549B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2767064C (fr) 2009-07-02 2017-11-07 Sanofi Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
JP5581390B2 (ja) * 2009-10-23 2014-08-27 イーライ リリー アンド カンパニー Akt阻害剤
WO2012136776A1 (en) 2011-04-07 2012-10-11 Bayer Intellectual Property Gmbh Imidazopyridazines as akt kinase inhibitors
US8927572B2 (en) * 2011-07-09 2015-01-06 Xuanzhu Pharma Co., Ltd. Crystal form I of salt of a dipeptidyl peptidase-IV inhibitor and preparation method and use thereof
MX346095B (es) 2011-09-12 2017-03-07 Merck Patent Gmbh Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
HUE034979T2 (en) 2011-09-12 2018-05-02 Merck Patent Gmbh Aminopyrimidine derivatives for use as modulators of kinase activity
US9580443B2 (en) 2012-11-16 2017-02-28 Merck Patent Gmbh Heterocyclic derivatives as modulators of kinase activity
EP3299362B1 (en) * 2012-11-16 2020-04-22 Merck Patent GmbH Imidazol-piperidinyl derivatives as modulators of kinase activity
ES2746756T3 (es) * 2013-03-11 2020-03-06 Merck Patent Gmbh Derivados de 6-[4-(1H-imidazol-2-il)piperidin-1-il]pirimidin-4-amina como moduladores de la actividad cinasa
BR112016015285A8 (pt) * 2014-02-11 2020-06-09 Merck Patent Gmbh pirimidina imidazol aminas como moduladores da atividade de quinase, seus usos e seu processo de preparação, composição farmacêutica, e kit
TW201718574A (zh) 2015-08-12 2017-06-01 美國禮來大藥廠 Cgrp受體拮抗劑
MX374576B (es) * 2016-05-20 2025-03-06 Taiho Pharmaceutical Co Ltd Derivado de 5h-pirrolo[2,3-d]pirimidin-6(7h)-ona novedoso.
BR112022017856A2 (pt) * 2020-03-17 2022-11-01 Jiangsu Hengrui Pharmaceuticals Co Ltd Derivado bicíclico fundido, método de preparação do mesmo e uso farmacêutico do mesmo
CN113444110B (zh) * 2020-03-25 2023-05-12 江苏恒瑞医药股份有限公司 四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
TW202328138A (zh) 2021-09-17 2023-07-16 大陸商江蘇恒瑞醫藥股份有限公司 稠合二環類衍生物的可藥用鹽、晶型及其製備方法
JPWO2024009977A1 (cg-RX-API-DMAC7.html) * 2022-07-05 2024-01-11

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス, インコーポレイテッド キナーゼ調節因子および使用方法
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
CA2590961C (en) 2004-12-28 2013-11-26 Exelixis, Inc. [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
US7423043B2 (en) * 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
WO2007125321A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
WO2007125310A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
PL2358710T3 (pl) 2012-12-31
AU2009314324A1 (en) 2010-05-20
WO2010056563A1 (en) 2010-05-20
MY161461A (en) 2017-04-14
US8148387B2 (en) 2012-04-03
TN2011000207A1 (en) 2012-12-17
EA018947B1 (ru) 2013-11-29
ZA201102549B (en) 2012-09-26
AU2009314324B2 (en) 2013-06-20
TW201022268A (en) 2010-06-16
PT2358710E (pt) 2012-10-01
ES2391704T3 (es) 2012-11-29
HRP20120738T1 (hr) 2012-10-31
EP2358710A1 (en) 2011-08-24
KR101334460B1 (ko) 2013-12-02
BRPI0921916A2 (pt) 2015-12-29
RS52520B (sr) 2013-04-30
HK1158203A1 (en) 2012-07-13
DOP2011000129A (es) 2016-02-29
CN102216302B (zh) 2013-08-21
IL211940A (en) 2014-01-30
AR074072A1 (es) 2010-12-22
CN102216302A (zh) 2011-10-12
CA2743019A1 (en) 2010-05-20
ECSP11011048A (es) 2011-06-30
MA32776B1 (fr) 2011-11-01
IL211940A0 (en) 2011-06-30
CA2743019C (en) 2013-08-13
JO2822B1 (en) 2014-09-15
CO6382114A2 (es) 2012-02-15
CR20110240A (es) 2011-06-09
UA100190C2 (en) 2012-11-26
JP5432275B2 (ja) 2014-03-05
EP2358710B1 (en) 2012-08-15
HN2011001247A (es) 2013-05-20
SI2358710T1 (sl) 2012-11-30
DK2358710T3 (da) 2012-09-03
PA8846901A1 (es) 2010-06-28
US20100120801A1 (en) 2010-05-13
TWI422587B (zh) 2014-01-11
NZ592062A (en) 2013-03-28
EA201170680A1 (ru) 2011-12-30
PE20110807A1 (es) 2011-10-31
MX2011005000A (es) 2011-05-25
KR20110074578A (ko) 2011-06-30
JP2012508274A (ja) 2012-04-05

Similar Documents

Publication Publication Date Title
CY1113409T1 (el) Αναστολεις ακτ και ρ70 s6 κινασης
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
CY1113386T1 (el) Αναστολεις πρωτεασωματος
CY1112828T1 (el) Ενωσεις αναστολης της μιτωτικης διαδικασιας
EA200970156A1 (ru) Пиридизиноновые производные
PH12015501484A1 (en) Heteroaryl compounds and uses thereof
TW201713640A (en) Bruton's tyrosine kinase inhibitors
CY1114539T1 (el) Η χρησιμοτητα των ιμιδαζοπυριδαζινοκαρβονιτριλιων ως αναστολεων κινασων
BR112012008385A2 (pt) inibidores de p13 cinase e uso dos mesmos.
ATE547415T1 (de) Inhibitoren der wechselwirkung zwischen mdm2 und p53
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
CY1111752T1 (el) Πυρρολοπυραζολες, δυναμικοι αναστολεις κινασης
EA201270590A1 (ru) Ингибиторы акт
UA112281C2 (uk) Стабільні інсектицидні композиції і способи їх отримання
MY153915A (en) Organic compounds
EA201200631A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
EA200870217A1 (ru) 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
DK2134691T3 (da) Quinolinonderivativer som parp- og tank-inhibitorer
EA201170227A1 (ru) Имидазолкарбоксамиды
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
PL1899329T3 (pl) Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych
UA109775C2 (xx) N-вмісні гетероарильні похідні як інгібітори jak3-кінази
MX2010010406A (es) Tetrahidrofenantridinonas y tetrahidrociclopentaquinolinonas como inhibidores de la polimerizacion de poli(adp-ribosa)polimerasa-1 y tubulina.